Sign in

CIK 0001649989

  • Non-accelerated filer
  • Smaller reporting company

Outlook Therapeutics, Inc.

Sign in to watch
Ticker
OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Sep 30
Incorporated
DE
Entity type
Operating
EIN
383982704
Phone
+1 609-619-3990
Business address
111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
Former names
Oncobiologics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 71 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2020-07-17 KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy Grant or award · Stock Option (Right to Buy) +450,000 450,000
2020-07-17 Huang Andong Director Grant or award · Stock Option (Right to Buy) +125,000 125,000
2020-07-17 HILZINGER KURT J Director Grant or award · Stock Option (Right to Buy) +210,000 210,000
2020-07-17 Haddadin Yezan Munther Director Grant or award · Stock Option (Right to Buy) +135,000 135,000
2020-07-17 Gangolli Julian S Director Grant or award · Stock Option (Right to Buy) +125,000 125,000
2020-07-17 Auffarth Gerd Director Grant or award · Stock Option (Right to Buy) +125,000 125,000
2020-07-15 Syntone Ventures LLC 10% owner Purchase +823,045 $1.22 $1000K 16,823,045
2020-07-01 Gangolli Julian S Director Grant or award · Stock Option (Right to Buy) +35,006 $0.99 $34K 35,006
2020-07-01 Huang Andong Director Grant or award · Stock Option (Right to Buy) +11,376 $0.99 $11K 11,376
2020-07-01 Auffarth Gerd Director Grant or award · Stock Option (Right to Buy) +19,874 $0.99 $20K 19,874
2020-06-19 Huang Andong Director Grant or award · Stock Option (Right to Buy) +25,000 25,000
2020-04-20 Gangolli Julian S Director Grant or award · Stock Option (Right to Buy) +25,000 25,000
2020-04-20 Auffarth Gerd Director Grant or award · Stock Option (Right to Buy) +25,000 25,000
2020-03-23 BioLexis Pte Ltd. Director Option exercise +29,358,621 50,965,058
2020-03-23 BioLexis Pte Ltd. Director Option exercise · Series A-1 Convertible Preferred Stock −68,112 0
2020-03-19 Evanson Jeff Chief Commercial Officer Grant or award +1,207,457 1,207,457
2020-03-19 Dagnon Terry Chief Operating Officer Grant or award +1,207,457 1,207,457
2020-03-19 BioLexis Pte Ltd. Director Returned to the company · Series A-1 Convertible Preferred Stock −68,112 0
2020-03-19 BioLexis Pte Ltd. Director Grant or award · Series A-1 Convertible Preferred Stock +68,112 68,112
2020-03-19 KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy Grant or award · Stock Option (Right to Buy) +216,435 216,435

Page 11 of 14 · 276 trades